ALK1 Receptor Antagonists for Selective Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic therapies lack effective compositions and methods to inhibit undesirable angiogenesis, particularly in specific tissues and disease states, and there is a need for targeted approaches to manage conditions like cancer, rheumatoid arthritis, and eye disorders.
Innovation Solution
Development of antagonists targeting the activin-like kinase 1 (ALK1)-mediated regulatory system, including ALK1 receptor antagonists and ligand antagonists, such as ALK1 ECD polypeptides and antibodies, to inhibit angiogenesis by binding to ALK1 ligands and interfering with their signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anti-angiogenic agents are used, then angiogenesis inhibition is achieved, but tissue selectivity is poor and side effects occur
Solution Approach 1:
The patent applies local quality by developing ALK1-specific antagonists that selectively inhibit angiogenesis in target tissues (tumor, inflamed joints, eye) while sparing other organs. The antagonists bind specifically to ALK1 receptors expressed in pathological angiogenic tissues, providing tissue-selective inhibition without the broad toxicity of traditional agents.
Solution Approach 2:
The patent uses ALK1 antagonists as intermediaries that specifically block the TGF-β superfamily signaling pathway (BMP9, BMP10, GDF5, GDF6, GDF7) involved in pathological angiogenesis. These antagonists mediate selective inhibition between the pro-angiogenic factors and their receptors, preventing harmful angiogenesis while allowing normal physiological processes to continue.
2Object-affected harmful factors
If broad-spectrum anti-angiogenic therapy is applied, then tumor angiogenesis is inhibited, but normal physiological angiogenesis is also suppressed
Solution Approach 1:
The ALK1 antagonists exhibit local quality by preferentially binding to ALK1 receptors that are overexpressed in tumor vasculature and pathological tissues, while having minimal impact on normal physiological angiogenesis. This selective binding profile allows inhibition of harmful angiogenesis while preserving essential blood vessel formation in healthy tissues.
Solution Approach 2:
The patent exploits parameter changes in receptor expression levels - ALK1 is highly expressed in pathological angiogenic tissues but at low levels in normal tissues. By designing antagonists with high affinity for ALK1, the therapy achieves selective inhibition based on this expression parameter difference, sparring normal physiological processes.
3Reliability
If multiple anti-angiogenic mechanisms are combined, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The ALK1 antagonists demonstrate multi-functionality by simultaneously targeting multiple ligands (BMP9, BMP10, GDF5, GDF6, GDF7) that all signal through the same ALK1 receptor. A single antagonist class provides broad coverage against diverse pro-angiogenic factors, achieving enhanced therapeutic efficacy without requiring combination of multiple different drugs or complex treatment protocols.
Data Source
AI summary
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.